Full Text:

 

¿µ³²ÀÇ´ëÇмúÁö Vol.24_No.2 Suppl. P.S652-657, Dec. 2007

Case Report

ÀڱðæºÎ¿¡ ¹ß»ýÇÑ Åõ¸í¼¼Æ÷¾Ï 1 ¿¹

A Case of Clear Cell Adenocarcinoma of the Uterine Cervix

¹Ú¼ºÃ¶, ¹ÚÀ±±â, À̵ÎÁø, À̽ÂÈ£
¿µ³²´ëÇб³ Àǰú´ëÇÐ »êºÎÀΰúÇб³½Ç
Ã¥ÀÓÀúÀÚ£ºÀ̽ÂÈ£, ´ë±¸±¤¿ª½Ã ³²±¸ ´ë¸í5µ¿ 317-1, ¿µ³²´ëÇб³ Àǰú´ëÇÐ »êºÎÀΰúÇб³½Ç
Tel: (053) 620-3431, Fax: (053) 654-0676
E-mail: shlee@med.yu.ac.kr

December 30, 2007

Abstract

Clear cell adenocarcinoma of cervix is a very rare malignancy of the uterine cervix. The etiology and pathogenesis are unclear. Clear cell adenocarcinomas have been reported most commonly in women with a history of in utero exposure to diethylstilbesterol (DES), these tumors also can develope in the absence of exposure to DES. These tumors account for 4% to 9% of adenocarcinomas of the cervix.
We report a case of clear cell adenocarcinoma in the uterine cervix of 40 years-old women who was not related to DES with a brief review of literature.

Key Words: Clear cell adenocarcinoma, Cervical cancer, DES

References

1. Silverberg SG, De Giorgi LS. Clear cell carcinoma of endometrium; clinical, pathologic, and ultrastructual findings. Cancer 1973 May; 31(5):1127-40.

2. ±èöÁß, ¹Úâ¼ö, ÀÌÁ¤¿ø, À̼öÈ£, À̼±ÁÖ, ±èº´±â µî. ¼º°æÇèÀÌ ¾ø´Â 22¼¼ ¿©¼º ÀڱðæºÎ¿¡¼­ ¹ß»ýÇÑ Åõ¸í¼¼Æ÷¾Ï 1¿¹. ´ëÇÑ»êºÎȸÁö 2004;47(7): 1409-14.

3. ³ª¼ö¹Ì, ¿À¼ºÈ¯, ±èÈï°ï, ¹®Çü¹è. Diethylstilbesterol°ú °ü·ÃÀÌ ¾ø´Â ÀڱðæºÎ Åõ¸í¼¼Æ÷¾Ï 1¿¹. ´ëÇÑ»êºÎȸÁö 2007;50(3):539-44.

4. Meyer R. Uber Adenom- and Karzinombildung and der Ampulle des Gartnerschen Ganges. Virchows Arch. F. Path. Anat 1903;174:270-94.

5. Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986 Apr;57(8):1584-93.

6. ÀÌÇý°æ, Â÷µ¿¼ö, ±è´ëÇö, ÃÖ¼º´ö, ÀÌ¿µÁø, ±è¿µ¹Î. ÀڱðæºÎ Åõ¸í¼¼Æ÷¾Ï 1¿¹. ´ëÇÑ»êºÎȸÁö 1987; 60:689-93.

7. Scully RE, Barlow JF. Mesonephroma ovarii. Am J Cancer 1939;35:1-21.

8. Reich O, Tamussino K, Lahousen M, Pickel H, Hass J, Winter R. Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB - IIB disease in women not exposed in utero to diethylstilbes- terol. Gynecol Oncol 2000 May;76(3):331-5.

9. Frosberg JG, Kalland T. Embryology of the genital tract in human and rodents; developmental effect of DES in pregnancy. New York: Thiema-Stratton;1981;1-15.

10. Herbst AL, Robboy SJ, Scully RE, Poskanzer DC. Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases. Am J Gynecol 1974 Jul;119(5):713-24.

11. Waggoner SE, Baunoch DA, Anderson SA, Leigh F, Zagaja VG. Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinoma of the vagina and cervix expressing wild-type P53. Ann Surg Oncol 1998 Sep;5(6):544-7.

12. Boyd J, Takahashi H, Waggoner SE, Jones LA, Hajek RA, Wharton JT, et al. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbesterol exposure in utero. Cancer 1996 Feb;77(3):507-13.

13. Hanselaar A, Von Loosbroek M, Schuurbiers O, Helmerhorst T, Bulten J, Bemhelm J. Clear cell adenocarcinoma of the vagina and cervix. Cancer 1997 Jul;79(11):2229-36.

14. Senekjian EK, Frey K, Herbst AL. Pelvic exenteration in clear cell adenocarcinoma of the vagina and cervix. Gynecol Oncol 1989 Sep; 34(3):413-6.

15. Okamoto Y, Hiroto S, Soejima T, Maeda Y, Takada H, Hishikawa Y, et al. Radiotherapy for adenocarcinoma of the uterine cervix. Nippon Igaku Hoshasen Gakkai Zasshi 1997 Dec;57(14):936-41.

16. Herbst AL, Norusis MJ, Rosenow PJ, Welch RR, Scully RE. An analysis of 346 cases of clear cell adenocarcinoma of the vagina and cervix with emphasis on recurrence and survival. Gynecol Oncol 1979 Apr;7(2):111-22.

17. Novak E, Woodruff JD, Novak ER. Probable mesonephric orign of certain female genital tumor. Am J Obstet Gynecol 1954 Nov;68: 1222-42.

18. Anderson B, Watring WG, Edinger DD Jr, Small EC, Netland AT, Safaii H. Development of DES-associated clear cell carcinoma: the importance of regular screening. Obstet Gynecol. 1979 Mar;53(3):293-9.